GlassScriptPhysician profile
Scott A Modena
NPI 1659339133
$2,078.03
in general payments reported to CMS, 2019-2025
22 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $209 · 2021: $311 · 2022: $105 · 2023: $226 · 2024: $532 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.08 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $561.01 | 2019-2025 | Xifaxan |
| Abbvie INC. | $370.03 | 2019-2025 | |
| Pfizer INC. | $184.37 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.18 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $149.13 | 2019-2024 | Stelara, Simponi, Remicade |
| Phathom Pharmaceuticals, INC. | $112.13 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $101.65 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $66.06 | 2019-2024 | |
| Braintree Laboratories, INC. | $64.20 | 2019-2023 | Suflave |
| Gilead Sciences, INC. | $49.63 | 2019-2020 | |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Merck Sharp & Dohme LLC | $38.38 | 2019 | |
| Celgene Corporation | $28.54 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $25.55 | 2019 | |
| Genzyme Corporation | $21.82 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $17.76 | 2022 | |
| Qol Medical, LLC | $17.30 | 2024 | Sucraid |
| Medtronic, INC. | $16.99 | 2023 | Gi Genius |
| Ge Healthcare | $16.82 | 2025 | |
| Madrigal Pharmaceuticals | $16.74 | 2025 | Rezdiffra |
| Ardelyx, INC. | $15.32 | 2023 | Ibsrela |
| Endogastric Solutions, INC | $13.21 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Modena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.